Designed for biological research and industrial applications, not intended for individual clinical or medical purposes.
Our peptide-based delivery platform is an integrated technology suite designed to solve one of the most critical challenges in modern therapeutics—how to safely and precisely deliver genetic medicines, proteins, and small molecules to the right cells. By combining programmable peptide engineering, modular delivery architectures, and advanced formulation capabilities, we provide end-to-end solutions that enable high-efficiency intracellular delivery, tissue-specific targeting, and superior manufacturability. Our platform supports a full spectrum of therapeutic modalities—including mRNA, siRNA, ASO, CRISPR RNPs, biologics, and small molecules—offering researchers and developers a powerful, non-viral alternative for next-generation drug development.
What Are Peptide-Based Delivery Systems?
Key mechanisms of peptide-based drug delivery, illustrating cell penetration, receptor-mediated targeting, membrane fusion for endosomal escape, and self-assembly into nanoparticles.
Peptide-based delivery systems are engineered therapeutic carriers composed of short, programmable amino-acid sequences purpose-built to transport genetic medicines, proteins, and small molecules across biological barriers. Unlike viral vectors or conventional lipid nanoparticles, peptide delivery systems leverage intrinsic biological functions—cell penetration, receptor targeting, membrane fusion, and self-assembly—to achieve highly specific and efficient payload delivery.
These systems can be rationally designed to:
- Bind and transport nucleic acids (mRNA, siRNA, ASO, CRISPR RNP)
- Deliver functional proteins or enzymes directly to the cytosol
- Penetrate hard-to-reach tissues, including tumor microenvironments and the central nervous system
- Exhibit superior stability and manufacturability, thanks to the chemical scalability of peptides
- Minimize immunogenicity and off-target effects through precision targeting and controlled release
As a fully programmable, non-viral modality, peptide-based delivery enables next-generation therapeutics that require precision, modularity, and safety—unlocking indications inaccessible to traditional delivery systems.
Platform Value: Why Peptide Delivery Matters
Core value pillars of our peptide-based delivery platform, including modular design, programmable engineering, broad payload compatibility, and scalable manufacturing readiness.
Our peptide-based delivery platform is designed to address the fundamental challenge of modern therapeutics: achieving safe, efficient, and precise delivery of complex modalities to the right cells and tissues. By integrating modular peptide engineering, programmable design principles, and scalable formulation strategies, our platform enables tailored delivery solutions across genetic medicines, biologics, and small-molecule therapeutics. This approach provides a flexible, non-viral alternative to conventional delivery systems while supporting rapid development and clinical translation.
Our platform creates a versatile, programmable delivery foundation that unlocks new therapeutic possibilities while reducing development risk and accelerating timelines.
- Modular Platform Design: Interchangeable peptide modules enable rapid customization of delivery systems to match specific payloads, targets, and disease biology.
- Programmable Peptide Engineering: Rational and AI-assisted peptide design allows precise tuning of stability, targeting, intracellular trafficking, and manufacturability.
- Broad Modality Compatibility: A single delivery platform supports mRNA, siRNA, ASO, CRISPR cargos, proteins, and small molecules without fundamental redesign.
- Precision Tissue Targeting: Targeting peptides enable organ- and cell-specific delivery, improving therapeutic index and minimizing systemic toxicity.
- Efficient Intracellular Delivery: Optimized CPP and fusogenic peptide systems enhance cellular uptake and endosomal escape for improved functional efficacy.
- Scalable Manufacturing Readiness: Fully synthetic, chemically defined peptide systems offer predictable quality, reproducibility, and seamless transition toward GMP production.
Modular Peptide Delivery Platform
Our peptide-based delivery platform is built around six synergistic technology modules. Each module offers specialized capabilities and can be combined to create a fully customized delivery system tailored to the biology of each disease and the requirements of each therapeutic payload.
CPP-based Delivery Platform
Cell-penetrating peptides (CPPs) designed for rapid membrane translocation and cytosolic delivery.
Service Capabilities
- Custom CPP discovery, optimization & engineering
- Charge, amphiphilicity & hydrophobicity tuning
- CPP–cargo conjugation and complexation strategies
- Stability, uptake, and intracellular trafficking studies
- in vitro and in vivo delivery performance evaluation
Deliverable Payload Types
- Nucleic acids: mRNA, saRNA, siRNA, ASO, DNA, CRISPR RNPs
- Proteins & biologics: enzymes, peptides, antibody fragments
- Small molecules requiring intracellular entry
Endosomal Escape & Fusogenic Peptide Platform
Membrane-active peptides enabling efficient release of therapeutic cargos from endosomes into the cytosol.
Service Capabilities
- Design of pH-responsive & fusogenic peptides
- Engineering of HA2-, KALA-, and INF7-like sequences
- Endosomal escape optimization
- Mechanistic validation via imaging and quantification assays
- Integration into CPP, LNP, polymer, or hybrid systems
Deliverable Payload Types
- mRNA / saRNA
- siRNA / ASO
- CRISPR-Cas RNP complexes
- Protein and enzyme therapeutics
Targeted Peptide Delivery Platform
Receptor-specific and tissue-targeting peptides for organ- and cell-type–precise delivery.
Service Capabilities
- Targeting peptide discovery via phage or mRNA display
- Design of BBB shuttles, tumor-penetrating and immune-cell targeting peptides
- Peptide-nanoparticle surface functionalization
- Receptor binding and targeting validation
- in vivo biodistribution and organ-targeting studies
Deliverable Payload Types
- mRNA, siRNA, ASO, CRISPR genetic medicines
- Proteins, cytokines, and enzymes
- Small molecules for tissue- or tumor-specific targeting
Self-Assembling Peptide Nanoparticle (SAPN) Platform
Peptides that self-assemble into nanostructures capable of encapsulating and protecting diverse therapeutic cargos.
Service Capabilities
- De novo SAPN design (β-sheet, α-helix, coiled-coil)
- Optimization of particle size, morphology, and stability
- Encapsulation of nucleic acids or proteins
- Serum stability, release kinetics, and structural characterization
- Scalable formulation development
Deliverable Payload Types
- mRNA / saRNA
- siRNA / ASO / DNA
- CRISPR RNP
- Proteins, peptides, and small molecules
Peptide-Lipid Hybrid LNP Platform
Next-generation lipid nanoparticles enhanced with peptides for improved targeting and intracellular delivery.
Service Capabilities
- Incorporation of CPPs, targeting, or fusogenic peptides into LNPs
- Peptide–lipid conjugate synthesis
- Optimization of stability, encapsulation efficiency, and biodistribution
- in vitro and in vivo functional testing
- Endosomal escape–enhanced LNP engineering
Deliverable Payload Types
- mRNA / saRNA
- siRNA / ASO
- CRISPR components
- Peptide–drug conjugates
Polymer–peptide hybrid carriers offering enhanced stability, controlled release, and tunable pharmacokinetics.
Service Capabilities
- Design and synthesis of peptide–polymer conjugates
- Formulation of micelles, hydrogels, and nanoparticles
- Controlled-release system engineering
- Stability, diffusion, and release profiling
- Custom hybrid platform development for specific indications
Deliverable Payload Types
- Small molecules (long-acting formulations)
- Proteins and peptides
- siRNA / DNA / ASO
- mRNA (select polymer systems)
Delivery Platform Module Overview
This table summarizes the six core peptide-based delivery modules within our platform, highlighting their primary mechanisms, compatible payloads, and key advantages. Together, these modules form a flexible, modular delivery framework that can be configured to meet diverse therapeutic needs.
| Delivery Module | Core Mechanism | Compatible Payloads | Key Advantages |
|---|
| CPP-Based Delivery | Direct membrane penetration | mRNA, siRNA, ASO, CRISPR RNP, proteins, small molecules | Fast cytosolic entry, high versatility |
| Fusogenic/Endosomal Escape Peptides | pH-triggered membrane disruption | RNA therapeutics, CRISPR, proteins | Strong endosomal escape efficiency |
| Targeted Peptide Delivery | Receptor-specific binding | All payload types | Organ/cell-type specificity, reduced toxicity |
| SAPN (Self-Assembling Peptide Nanoparticles) | Nanostructure self-assembly | RNA, proteins, small molecules | Tunable structure, high stability |
| Peptide-Lipid Hybrid LNP | LNP enhanced with peptides | mRNA, siRNA, CRISPR | Improved targeting & intracellular delivery |
| Peptide-Polymer Hybrid Systems | Polymer-peptide conjugates | Proteins, small molecules, RNA | Controlled release, long-acting formulations |
Payload Compatibility Matrix
This matrix illustrates the compatibility between different therapeutic payload types and each delivery module, providing a clear view of how our peptide-based technologies support multiple modalities. It highlights the versatility of the platform across RNA therapeutics, gene editing, biologics, and small-molecule delivery.
| Payload Type | CPP | Fusogenic | Targeting | SAPN | Peptide-LNP | Peptide-Polymer |
|---|
| mRNA / saRNA | ✓✓✓ | ✓✓✓ | ✓✓ | ✓✓ | ✓✓✓ | ✓ |
| siRNA / ASO | ✓✓✓ | ✓✓✓ | ✓✓ | ✓✓ | ✓✓✓ | ✓ |
| CRISPR RNP | ✓✓ | ✓✓ | ✓ | ✓ | ✓✓ | – |
| Proteins / Enzymes | ✓✓✓ | ✓✓ | ✓ | ✓✓ | – | ✓✓✓ |
| Antibody Fragments / Intrabodies | ✓✓ | ✓✓ | ✓ | ✓ | – | ✓✓ |
| Peptides / Peptide Therapeutics | ✓✓✓ | ✓ | ✓✓ | ✓✓ | – | ✓✓ |
| Small Molecules | ✓✓ | – | ✓ | ✓ | – | ✓✓✓ |
| Combination Payloads | ✓✓ | ✓✓ | ✓ | ✓ | ✓ | ✓ |
Legend: ✓= compatible ✓✓= high compatibility ✓✓✓= optimal
Technology Capabilities
Our integrated technology stack spans the entire pipeline—from design to in vivo validation.
Peptide Discovery & Screening
- AI-driven peptide sequence design
- Phage display and mRNA display (RaPID)
- High-throughput peptide library generation
- Mechanistic screening for cell penetration, receptor binding, and membrane fusion
Peptide Engineering & Optimization
- Sequence optimization of charge, amphiphilicity, and hydrophobicity
- Cyclization, D-amino acid incorporation, and backbone stabilization
- Enzyme-responsive and pH-responsive peptide linkers
- Conjugation chemistries for nucleic acids, proteins, and small molecules
Assembly & Formulation
- Self-assembling peptide nanoparticles (SAPNs)
- Peptide–lipid hybrid LNP formulation
- Peptide–polymer nanoparticle fabrication
- Peptide–drug conjugates (PDCs)
- Encapsulation and complexation optimization for mRNA, siRNA, and CRISPR cargos
in vitro Evaluation Platform
- Cellular uptake assays
- Endosomal escape quantification
- Transfection efficiency evaluation
- Target binding and receptor engagement studies
- Cytotoxicity, hemolysis, and serum stability assays
in vivo Validation
- Biodistribution and organ-targeting analysis
- Pharmacokinetics (PK) and pharmacodynamics (PD) modeling
- mRNA expression and gene-silencing studies
- Tumor penetration and CNS delivery assessment
- Immunogenicity and safety profiling
Why Partner With Us?
Modular Platform Design
Our peptide delivery platform enables rapid customization and seamless assembly of delivery modules tailored to each therapeutic program.
Broad Payload Compatibility
A single, unified system supports RNA therapeutics, gene-editing cargos, proteins, and small molecules across multiple modalities.
Precision Tissue Targeting
Engineered targeting peptides enable organ- and cell-specific delivery while minimizing off-target exposure.
Efficient Intracellular Delivery
Optimized cell-penetrating and fusogenic peptides maximize cytosolic delivery and functional therapeutic outcomes.
Scalable Manufacturing Readiness
Chemically defined peptide systems support robust scale-up and smooth transition toward GMP production.
Flexible Partnership Models
We offer custom development, co-development, and platform licensing options aligned with your scientific and IP strategy.
How We Work
A structured, milestone-driven process designed to accelerate delivery system development while maintaining scientific rigor and operational clarity.
1
Project Consultation & Requirement Mapping
- Understand therapeutic modality (mRNA, siRNA, CRISPR, protein, small molecule)
- Define delivery challenges and target tissues
- Clarify project scope, delivery goals, timelines, and IP arrangements
2
Peptide Module Selection & Preliminary Design
- Select CPP, targeting, fusogenic, or SAPN modules
- AI-assisted peptide design and sequence optimization
- Preliminary design report for client approval
3
Custom Engineering & Formulation Development
4
in vitro Evaluation
- Cellular uptake assessment
- Endosomal escape evaluation
- Transfection or functional efficacy testing
- Cytotoxicity and hemolysis analysis
- Receptor-specific targeting validation
- Deliverable:Comprehensive in vitro data package
5
in vivo Validation (Optional)
- Biodistribution and organ-targeting studies
- Pharmacokinetics (PK) and pharmacodynamics (PD) evaluation
- mRNA expression or gene-silencing performance assessment
- Safety and immunogenicity profiling
- Deliverable: in vivo data report and recommended next steps
6
Optimization & Scale-Up Feasibility
- Peptide sequence refinement
- Enhanced targeting or delivery efficiency
- Manufacturability and scalability assessment
- Preclinical package preparation
Therapeutic Applications
Our platform is engineered to support the next generation of genetic medicines and precision therapeutics.
Antisense and siRNA Therapeutics
- Enhance Cellular Uptake: CPP–ASO and CPP–siRNA conjugates efficiently cross cellular membranes to overcome poor intrinsic permeability.
- Improve Tissue Targeting: Targeting peptides (e.g., RGD, Angiopep-2) direct oligonucleotides to tumors, CNS, liver, or muscle tissues.
- Increase Bioavailability: Peptide conjugation protects ASOs and siRNAs from nuclease degradation, improving systemic stability and exposure.
- Facilitate Endosomal Escape: Fusogenic peptides (e.g., INF7, GALA) promote cytosolic release, enhancing gene-silencing potency.
mRNA and RNA-Based Therapeutics
- Enable Efficient Cytosolic Delivery: Peptide-based carriers promote rapid intracellular transport of mRNA beyond endosomal sequestration.
- Enhance Expression Efficiency: Optimized CPP and fusogenic modules maximize mRNA translation by improving cytoplasmic availability.
- Improve Tissue Selectivity: Targeting peptides enable organ- or cell-specific delivery beyond liver-dominant LNP systems.
- Increase Stability and Safety: Fully synthetic peptide systems reduce immunogenicity and improve formulation stability.
CRISPR and Gene Editing Therapeutics
- Support RNP Delivery: CPP-based systems enable direct delivery of CRISPR-Cas RNPs without viral vectors.
- Improve Editing Efficiency: Enhanced endosomal escape increases nuclear access and genome-editing outcomes.
- Reduce Off-Target Effects: Targeted peptide delivery limits systemic exposure and improves tissue precision.
- Enable Transient Expression: Non-viral peptide systems support controlled, transient gene editing with improved safety profiles.
Oncology and Precision Cancer Therapy
- Enhance Tumor Targeting: Tumor-homing and tumor-penetrating peptides (e.g., RGD, iRGD, LyP-1) selectively accumulate in cancer tissues.
- Improve Tumor Penetration: Peptides enable deep penetration into solid tumors and dense tumor microenvironments.
- Enable Microenvironment-Responsive Delivery: Enzyme- or pH-responsive peptides activate payload release within tumors.
- Reduce Systemic Toxicity: Targeted peptide delivery minimizes off-target exposure while enhancing therapeutic index.
Central Nervous System (CNS) and BBB Delivery
- Facilitate BBB Transport: BBB-shuttle peptides (e.g., Angiopep-2, TfR-binding peptides) enable transcytosis across the blood–brain barrier.
- Enable Intracellular Delivery: CPP modules support cytosolic delivery of RNA and proteins in neuronal and glial cells.
- Improve CNS Bioavailability: Peptide-mediated transport increases brain exposure compared to conventional delivery systems.
- Support Diverse Modalities: Compatible with RNA therapeutics, gene-editing cargos, and protein-based treatments.
Protein and Enzyme Replacement Therapies
- Enable Cytosolic Protein Delivery: CPPs transport functional proteins and enzymes directly into the cytoplasm.
- Overcome Endosomal Trapping: Fusogenic peptides promote intracellular release of biologics.
- Expand Therapeutic Scope: Enables treatment of intracellular targets inaccessible to conventional biologics.
- Improve Functional Outcomes: Enhanced intracellular delivery increases enzymatic activity and therapeutic efficacy.
Delivery Platform Partnerships
Collaborate with us to unlock next-generation delivery solutions for RNA therapeutics, gene editing, protein biologics, and targeted small-molecule therapies. Our peptide-based delivery platform is designed for flexible integration — whether you need custom peptide engineering, delivery optimization, or full program co-development.
We work with biotechnology companies, pharmaceutical partners, and academic innovators to accelerate therapeutic development from concept to IND and beyond. With modular design, scalable manufacturing, and deep delivery expertise, our platform can be seamlessly adapted to diverse therapeutic pipelines. Partner with our team to design and deploy customized peptide-based delivery solutions for your therapeutic programs.
FAQs
1. What types of therapeutics can your peptide-based delivery platform support?
Our platform is compatible with a wide range of modalities, including:
mRNA and self-amplifying RNA
siRNA, ASO, and DNA oligonucleotides
CRISPR RNPs and gene-editing complexes
Recombinant proteins, enzymes, and peptides
Small molecules requiring targeted or intracellular delivery
2. Can your platform deliver CRISPR-Cas9 RNPs?
Yes.Our CPP-based and fusogenic platforms are highly efficient for delivering Cas9 RNPs into the cytosol with improved endosomal escape.
3. Do you design custom peptides for delivery?
Yes.We provide AI-guided sequence design, module selection, optimization, and synthesis for:
CPPs
Targeting ligands
Fusogenic peptides
Self-assembling peptide scaffolds
Peptide conjugates for LNP or polymer systems
4. Can you develop delivery systems for hard-to-reach tissues like CNS or tumors?
Absolutely.We provide:
BBB-penetrating peptides (e.g., TfR, Angiopep-2 analogs)
Tumor-targeting & penetrating peptides (RGD, iRGD, NGR, LyP-1)
MMP-responsive activation motifs
5. Do you provide GMP peptide or nanoparticle manufacturing?
We provide:
Research-grade peptide & nanoparticle manufacturing
Tech transfer to GMP-certified partners
Scale-up guidance
